Retrophin (NASDAQ:RTRX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, January 10th.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Retrophin from a “strong sell” rating to a “hold” rating in a report on Thursday, January 4th. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $44.00 target price on shares of Retrophin in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $44.00.
Shares of Retrophin (NASDAQ RTRX) traded down $0.05 during mid-day trading on Wednesday, hitting $23.86. The stock had a trading volume of 166,355 shares, compared to its average volume of 227,584. Retrophin has a 12 month low of $15.55 and a 12 month high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.21). The firm had revenue of $40.34 million during the quarter, compared to the consensus estimate of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. Retrophin’s revenue was up 18.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) EPS. equities analysts predict that Retrophin will post -1.24 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new stake in shares of Retrophin during the third quarter worth about $203,000. SG Americas Securities LLC raised its position in shares of Retrophin by 1.8% during the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 146 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Retrophin during the third quarter worth about $212,000. Legal & General Group Plc raised its position in shares of Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Retrophin during the third quarter worth about $249,000.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/01/retrophin-rtrx-upgraded-to-buy-at-bidaskclub.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.